Anti-malarial drugs are medications used for the treatment and prevention of malaria infection. They are also known as anti-malarials. These drugs are used for routine intermittent treatment of specific groups in endemic regions. Anti-malarial drugs are also used for prevention of infection in individuals who travel or visit a malaria-endemic region. Efficacious antimalarial therapy not only reduces the morbidity and mortality of malaria, but also reduces the risk of resistance to antimalarial drugs.

The global anti-malarial drugs market is gradually developing due to the surge in prevalence rate of malaria globally. Favorable government regulations, development of multi-drug resistance (MDR), and increase in research, development, and innovation in terms of anti-malaria therapeutics is anticipated to supplement market growth. However, possible side effects of anti-malaria drugs such as anxiety, dizziness insomnia, and others impede the growth of this market.

The global antimalarial drug market is segmented on the basis of drug type, malaria type, mechanism of action, distribution channel, and geography. Based on drug type, it is divided into quinine, chloroquine, pyrimethamine, amodiaquine, proguanil, mefloquine, sulfonamide, artemisinin & derivatives, atovaquone, primaquine, halofantrine, doxycycline, and clindamycin. On the malaria type, it is classified into plasmodium falciparum, plasmodium vivax, plasmodium malariae and plasmodium ovale. By mechanism of action, it is bifurcated into resistance and prevention. Furthermore, by distribution channel the antimalarial drug market is categorized into hospital pharmacy, retail pharmacy, e-commerce, and others. By geography, this market is analyzed across North America, Europe, Asia Pacific, and LAMEA. These regions are further analyzed across the globe at country level to determine the market size and forecast for each segment and sub segment of the market.

Comprehensive competitive analysis and profiles of major market players such as GlaxoSmithKline Plc, Ranbaxy Laboratories, Zydus Cadila, Alvizia Health Care, Bayer AG, Pfizer, Inc., Ipca Laboratories Ltd, Merck KGaA, F. Hoffmann-La Roche AG, and Novartis AG are also provided in this report.

Key Benefits

• The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
• Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
• Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
• Extensive analysis by product elucidates the use of anti-malarial drugs in medical settings.

Anti-malarial Drug Market Key Segments:

By Drug Type

• Quinine
• Chloroquine
• Pyrimethamine
• Amodiaquine
• Proguanil
• Mefloquine
• Sulfonamide
• Artemisinin & Derivatives
• Atovaquone
• Primaquine
• Halofantrine
• Doxycycline
• Clindamycin

By Malaria Type

• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium Malariae
• Plasmodium Ovale

By Mechanism of Action

• Resistance
• Prevention

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• E-Commerce
• Others

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Taiwan
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Turkey
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA